ATLANTA--(BUSINESS WIRE)--

Seattle Genetics, Inc. (SGEN) today highlighted clinical data from two antibody-drug conjugate (ADC) programs in development by Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) that utilize Seattle Genetics technology. The data were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 8-11, 2012 in Atlanta, GA. Phase I data from both ADCs, an anti-CD22 ADC (DCDT2980S, RG7593) and an anti-CD79b ADC (DCDS4501A, RG7596), demonstrated antitumor activity in relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) patients at generally well-tolerated doses. These ADC programs are currently being evaluated in a phase II clinical trial for patients with relapsed or refractory B-cell NHL.

Genentechs phase I data and their advancement of these two ADCs into phase II clinical development, as well as their utilization of our technology in six other clinical-stage programs,illustrates their commitment to ADCs as an innovative, targeted approach to treat cancer,saidEric Dobmeier, ChiefOperatingOfficer of Seattle Genetics. Across our ADC collaborations, there is broad potential for our industry-leading technologyto address thesignificant needformore effective and better tolerated treatment options.

Anti-CD22-MMAE and anti-CD79b-MMAE are ADCs designed to deliver potent cytotoxic treatment to targeted cells with improved tolerability. With over a decade of experience and knowledge in ADC innovation, Seattle Genetics has developed proprietary technology employing synthetic cytotoxic agents, such as monomethyl auristatin E (MMAE), and stable linker systems that attach these cytotoxic agents to the antibody. Seattle Genetics linker systems are designed to be stable in the bloodstream and release the potent cell-killing agent once inside targeted cancer cells. This approach is intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy while enhancing antitumor activity. ADCETRIS (brentuximab vedotin) is the first drug approved utilizing Seattle Genetics ADC technology.

A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (Abstract #56)

A phase I clinical trial is being conducted to evaluate the safety and activity of DCDS4501A in patients with relapsed or refractory B-cell NHL. DCDS4501A is an ADC consisting of an anti-CD79b monoclonal antibody conjugated to the cytotoxic agent MMAE using Seattle Genetics ADC technology. In this analysis, 47 patients were evaluable for safety and 32 were evaluable for efficacy.

Key findings included:

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (Abstract #59)

A phase I clinical trial is being conducted to evaluate the safety and activity of DCDT2980S in patients with relapsed or refractory B-cell NHL. DCDT2980S is an ADC candidate consisting of an anti-CD22 monoclonal antibody conjugated to the cytotoxic agent MMAE using Seattle Genetics ADC technology. In this analysis, 43 patients were evaluable for safety and 33 were evaluable for efficacy.

Key findings included:

View original post here:
Seattle Genetics Highlights Data Presentations from Genentech ADC Collaborator Programs at ASH Annual Meeting

Comments are closed.